1125 related articles for article (PubMed ID: 8605522)
1. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
2. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
3. [Community trial for safety and immunogenicity of oral-administered lyophilized rBS-WC cholera vaccine].
Chen Q; Yu S; Wang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 1996 Nov; 30(6):330-3. PubMed ID: 9388905
[TBL] [Abstract][Full Text] [Related]
4. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.
Savarino SJ; Hall ER; Bassily S; Brown FM; Youssef F; Wierzba TF; Peruski L; El-Masry NA; Safwat M; Rao M; El Mohamady H; Abu-Elyazeed R; Naficy A; Svennerholm AM; Jertborn M; Lee YJ; Clemens JD
J Infect Dis; 1999 Jan; 179(1):107-14. PubMed ID: 9841829
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
[TBL] [Abstract][Full Text] [Related]
7. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
8. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
[TBL] [Abstract][Full Text] [Related]
9. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
10. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
Qadri F; Ahmed T; Ahmed F; Begum YA; Sack DA; Svennerholm AM;
Vaccine; 2006 Mar; 24(10):1726-33. PubMed ID: 16257098
[TBL] [Abstract][Full Text] [Related]
11. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
[TBL] [Abstract][Full Text] [Related]
12. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers.
Pitisuttithum P; Migasena S; Suntharasamai P; Supanaranond W; Desakorn V; Prayurahong B
Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):201-5. PubMed ID: 2609209
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
[TBL] [Abstract][Full Text] [Related]
14. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
15. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.
Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Al Tarique A; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
Vaccine; 2007 Jan; 25(2):231-8. PubMed ID: 16996172
[TBL] [Abstract][Full Text] [Related]
16. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru.
Begue RE; Castellares G; Ruiz R; Hayashi KE; Sanchez JL; Gotuzzo E; Oberst RB; Taylor DN; Svennerholm AM
Vaccine; 1995 May; 13(7):691-4. PubMed ID: 7668039
[TBL] [Abstract][Full Text] [Related]
17. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.
Hall ER; Wierzba TF; Ahrén C; Rao MR; Bassily S; Francis W; Girgis FY; Safwat M; Lee YJ; Svennerholm AM; Clemens JD; Savarino SJ
Infect Immun; 2001 May; 69(5):2853-7. PubMed ID: 11292698
[TBL] [Abstract][Full Text] [Related]
18. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
19. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians.
Sanchez JL; Hayashi KE; Kruger HF; Meza R; English CK; Vidal W; Svennerholm AM; Taylor DN
Trans R Soc Trop Med Hyg; 1995; 89(5):542-5. PubMed ID: 8560536
[TBL] [Abstract][Full Text] [Related]
20. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
